Literature DB >> 3352273

Chordoma: natural history and treatment results in 33 cases.

A Azzarelli1, V Quagliuolo, S Cerasoli, R Zucali, P Bignami, V Mazzaferro, G Dossena, L Gennari.   

Abstract

Thirty-three chordomas were observed at the Istituto Nazionale Tumori of Milan from 1933 to 1983: 27 sacrococcygeal, 3 spheno-occipital, and 3 vertebral. The male:female ratio was 2.7, and the median age was 63 yr for patients with sacrococcygeal and 35.2 yr for those with nonsacral chordomas. After pathologic reassessment, distinct cytologic patterns were found: physaliphorous, syncytial, and mixed subtypes, with variable degrees of cytologic atypia. However, no evident difference in survival was documented in relation to these cytohistologic features. Four cases had a prior traumatic fracture, and the pathogenetic role of trauma is stressed. Eight cases were operated with adequate surgery and only three recurred, whereas of 11 inadequate operations, 10 developed local relapse. However, follow-up for recent adequate operations is short. Radiation therapy seemed to be effective with adjuvant or palliative aims. No chemotherapeutic regimen achieved any result; one case had a short complete remission after cis-dichlorodiammineplatinum + vinblastine + bleomycin (PVB). This analysis confirms the possibility of achieving radicality with high resection of the sacrum for lesions confined below the second sacral vertebra. Nonsacral chordomas were all unresectable. The best treatment for unresectable lesions seems to be palliative surgery plus radiotherapy.

Entities:  

Mesh:

Year:  1988        PMID: 3352273     DOI: 10.1002/jso.2930370311

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  31 in total

1.  Clinical significance of a wide excision policy for sacrococcygeal chordoma.

Authors:  Shunzo Osaka; Osamu Kodoh; Hideyuki Sugita; Eiji Osaka; Yoshiyuki Yoshida; Junnosuke Ryu
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-16       Impact factor: 4.553

Review 2.  An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.

Authors:  Mojdeh Safari; Alireza Khoshnevisan
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

3.  The extended posterior approach for resection of sacral tumours.

Authors:  S P Mohanty; Madhava Pai Kanhangad; Raghuraj Kundangar
Journal:  Eur Spine J       Date:  2018-11-20       Impact factor: 3.134

4.  The role of chemotherapy in pediatric clival chordomas.

Authors:  Girish Dhall; Mercedes Traverso; Jonathan L Finlay; Lisa Shane; Ignacio Gonzalez-Gomez; Rima Jubran
Journal:  J Neurooncol       Date:  2010-11-05       Impact factor: 4.130

Review 5.  Immunotherapy as a Potential Treatment for Chordoma: a Review.

Authors:  Shalin S Patel; Joseph H Schwab
Journal:  Curr Oncol Rep       Date:  2016-09       Impact factor: 5.075

Review 6.  Infantile clivus chordoma without clivus involvement: case report and review of the literature.

Authors:  D Kombogiorgas; E J St George; S Chapman; M English; G A Solanki
Journal:  Childs Nerv Syst       Date:  2006-03-25       Impact factor: 1.475

Review 7.  Pediatric cervical chordoma: report of two cases and a review of the current literature.

Authors:  Gwi Hyun Choi; Moon-Sool Yang; Do Heum Yoon; Hyun Chyul Shin; Keung Nyun Kim; Seong Yi; Dong Yeop Lee; Poong Gi Ahn; Yoon Ha
Journal:  Childs Nerv Syst       Date:  2010-01-22       Impact factor: 1.475

8.  Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.

Authors:  Ming-Xiang Zou; An-Bo Peng; Guo-Hua Lv; Xiao-Bin Wang; Jing Li; Xiao-Ling She; Yi Jiang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

Review 9.  Imatinib in the treatment of solid tumours.

Authors:  Florence Duffaud; Axel Le Cesne
Journal:  Target Oncol       Date:  2009-01-27       Impact factor: 4.493

10.  Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients.

Authors:  Virginia Ferraresi; Carmen Nuzzo; Carmine Zoccali; Ferdinando Marandino; Antonello Vidiri; Nicola Salducca; Massimo Zeuli; Diana Giannarelli; Francesco Cognetti; Roberto Biagini
Journal:  BMC Cancer       Date:  2010-01-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.